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Abstract 
Gastrointestinal stromal tumors (GISTs) are
known to be poorly responsive to conventional
chemotherapy  and  historically  considered
resistant to radiotherapy. In the past the main-
stay of GIST treatment was surgery, but the
introduction  of  tyrosine  kinase  inhibitors
(TKIs)  imatinib  and  sunitinib  marked  the
beginning of a new era in the treatment of
GIST patients. To date, radiotherapy for GIST
has not been administered in clinical practice
except for limited palliative settings and there
are  no  clear  data  on  the  administration  of
radiotherapy,  alone  or  in  combination  with
TKIs, with a purely cytoreductive intent. We
describe  the  clinical  case  of  a  48-year-old
woman  with  metastatic  GIST  treated  with
external radiotherapy in a critical supraclavic-
ular tumor localization progressively increas-
ing  in  size  with  several  symptoms  and  not
responsive  to  systemic  TKI  therapies.  We
obtained an initial shrinkage of the mass and
subsequent  stabilization  with  an  immediate
and clear clinical benefit. Although the histor-
ical medical literature considered GISTs resist-
ant to radiation therapy, our clinical case sug-
gests  this  treatment  may  be  appropriate  in
selected patients.
Introduction
Gastrointestinal stromal tumors (GISTs) are
the most common mesenchymal tumors of the
gastrointestinal tract. They originate from the
intestinal cell of Cajal, an intestinal pacemak-
er cell, and are usually characterized by specif-
ic abnormalities of the KIT and PDGFR-alpha
(PGDFRA) receptors that represent the main
oncogenic events and prime therapeutic tar-
gets.1-2
Tumor resection is the treatment of choice
for localized disease. The risk of recurrence is
identified evaluating the tumor mitotic index,
size  and  site  of  origin.3 Although  previously
considered refractory to any treatment, GIST
patients may now benefit from tyrosine kinase
inhibitors  imatinib  and  sunitinib  that  have
revolutionized the natural history of these neo-
plasms.4-5 Other molecules have also been test-
ed and new therapeutic agents are still under
evaluation in these tumors.6-7
In  the  pre-imatinib  era,  conventional
chemotherapic agents tested in GISTs showed
very  poor  results.8 Moreover  the  impact  of
radiotherapy  on  GIST  outcome  is  still
unknown.  GISTs  are  generally  considered
resistant  to  radiotherapy  so  this  treatment
does not play a prominent role in tumor man-
agement except in limited palliative settings.
Here, we describe the case of a 48-year-old
woman  with  a  complex  history  of  multi-
metastatic  gastrointestinal  stromal  tumor
since  2004  who  developed  a  progressively
increasing mass causing worsening symptoms
and was successfully treated by radiotherapy.
Case Report
In  September  2004  a  48-year-old  woman
underwent  surgical  resection  of  a  uterine
fibroma. In the course of the procedure, a large
mass was detected in the ileum and resected.
During  abdominal  cavity  exploration  many
peritoneal nodules were found but they were
not sampled or removed.The histology report
specified  gastrointestinal  stromal  tumor
(GIST) of the ileum (maximum diameter: 18
cm, mitotic index: >10/50 HPF). Tumor geno-
typing with sequencing for mutations in KIT
(exons 9, 11, 13 and 17) and PDGFRA (exon
18)  disclosed  a  deletion  c.1657-1674del
(p.Tyr553_Lys558 del.) at exon 11 of the KIT
gene.  Treatment  with  imatinib  400  mg  was
then started with a good radiological response
so the patient underwent a new surgical inter-
vention and all the peritoneal localizations of
GIST were resected (R0) 6 months after start-
ing  imatinib.  Immunohistochemistry  con-
firmed the diagnosis of GIST for all peritoneal
nodules. Treatment with imatinib was contin-
ued and the patient was followed with periodic
CT scans until October 2007 when a retroperi-
toneal mass of about 8 cm was detected. In
November 2007 she underwent a third surgical
intervention  that  was  referred  as  complete
resection of the retroperitoneal mass, positive
for  GIST  with  a  high  mitotic  index  (>10/50
HPF). In January 2008 the patient was referred
to our institution. Considering the two relaps-
es during imatinib treatment and the absence
of signs of histological response to therapy, we
increased the imatinib dose to 800 mg/day.
Unfortunately a new CT scan in July 2008
documented another peritoneal relapse so she
started a second line treatment with sunitinib.
No  response  to  therapy  was  obtained.  The
patient was also enrolled in a clinical trial with
nilotinib for 4 months and then she was treat-
ed with sorafenib off label but even these new
agents failed to yield a clear benefit.
During the history of her disease, a CT scan
disclosed a left supraclavicular mass of 14 mm
suspected for GIST localization that progres-
sively  increased  to  56  mm  when  it  became
deeply symptomatic with local pain and initial
dysphagia (Figure 1A). Radiological imaging
showed a mild compression of the jugular vein
without a clear separating plane between the
mass and the trachea. Because of symptoms
development, a rapid increase in the size of
the mass in 5 months and the lack of surgical
options, we administered external beam radio-
therapy combined with sorafenib at a dose of
400  mg/bid  starting  in  October  2010.
Cytoreductive radiation therapy was given at a
fraction of 25¥200 cGy with a total dose of 5000
cGy. The treatment was well-tolerated and the
patient referred an early benefit from radio-
therapy with a marked improvement of pain
and a resolution of the dysphagia. The CT scan
performed  after  the  end  of  the  radiotherapy
showed a decrease in size of the supraclavicu-
lar mass from 56¥39 mm to 44¥31 mm (Figure
1B).  Despite  a  systemic  progression  of  dis-
ease, the radio-treated mass remained stable
at the following radiological controls and she
has had no further symptoms at this site.
Rare Tumors 2011; volume 3:e49
Correspondence: Cristian Lolli,
Department  of  Hematology  and  Oncology
Sciences  L.A.Seràgnoli,  S.Orsola-Malpighi
Hospital, University of Bologna, via Massarenti 9,
40138 Bologna, Italy. 
Tel. + 39.051 6363680 - Fax: + 39.051 6364037.
E-mail: cristian_lolli@libero.it
Key  words:  gastrointestinal  stromal  tumors;
radiotherapy.
Conflict of interest: the authors report no con-
flicts of interest. 
Received for publication: 2 August 2011.
Accepted for publication: 26 September 2011.
This work is licensed under a Creative Commons
Attribution NonCommercial 3.0 License (CC BY-
NC 3.0).
©Copyright C. Lolli et al., 2011
Licensee PAGEPress, Italy
Rare Tumors 2011; 3:e49
doi:10.4081/rt.2011.e49[page 154] [Rare Tumors 2011; 3:e49]
Discussion 
We described a case of an unusual metasta-
tic localization of GIST not responsive to sys-
temic  treatments  and  successfully  controlled
by external beam radiotherapy.
The advent of tyrosine kinase inhibitors has
revolutionized  the  treatment  of  GIST  clearly
marking two periods in the history of these
tumors: the pre- and the post- imatinib era. So,
the main treatments of GIST are surgery, in
case  of    localized  disease  and  responding
metastatic lesions, and medical therapies with
TKIs inhibitors for not resectable and metasta-
tic  GISTs.  Conventional  treatments  like
chemotherapy and radiotherapy were quickly
outclassed by target therapies due to the huge
differences in their efficacy.8
Radiation  therapy  was  historically  consid-
ered to have minimal activity in these tumors.
The main reason for the scant use of radiation
therapy in GIST is that the pattern of metasta-
sis in the liver and peritoneum involves fields
too large to be amenable to radiation therapy.9
In 2002, Dematteo et al. reported that radio-
therapy may have some role in the palliation of
patients with bleeding from peritoneal recur-
rence  or  with  painful  disease  localizations.8
Literature  reports  on  radiation  therapy  in
GISTs are limited to palliation of bone metas-
tases,  often  in  association  with  biphospho-
nates.10-11
In fact, radiotherapy in the management of
GIST patients is currently restricted to sympto-
matic palliation and has not clearly been inves-
tigated with a purely cytoreductive intent.8,10-11
In 2001 Shioyama et al.12 described a case of a
retroperitoneal  GIST  treated  with  primary
radiotherapy (5100 cGy) but also with arterial
chemotherapy  and  immunotherapy  (OK432).
No change in tumor size was reported on early
computed  tomography  whereas  CT  scan  at
long-term  follow-up  revealed  a  marked
decrease of tumor size. The only recent experi-
ence of radiotherapy in association with ima-
tinib  with  a  potentially  curative  intent  was
described by Ciresa et al.13 in a patient with
GIST of the rectum who obtained a complete
pathological response. To our knowledge, no
data are available on radiotherapy in esopha  -
geal GISTs. 
In the adjuvant setting, Pollock et al. report-
ed on a case of adjuvant postoperative radio-
therapy in a rectal GIST treated by incomplete
surgical resection.14 They performed radiation
therapy due to the risk of local recurrence after
a subtotal resection. The patient was reported
to be disease-free two years after the end of
postoperative radiotherapy. 
The  clinical  case  described  herein  shows
that radiotherapy may have a role as a cytore-
ductive  therapy  in  GISTs.  We  adopted  this
unusual approach in this particular site due to
the onset of worsening symptoms and lack of
therapeutic options in a progressive disease.
The patient gained an early benefit from radio-
therapy but the most impressive outcome was
that the supraclavicular localization that had
progressively  increased  before  radiotherapy
resulted decreased at the first CT scan after
radiation  treatment  and  this  response  has
been maintained to date. We now suggest that
radiotherapy should be considered as a treat-
ment to obtain a cytoreductive effect or disease
control in selected cases especially when sys-
temic treatments are ineffective as in our GIST
patient.  The  possibility  of  obtaining  tumor
shrinkage  or  disease  stabilization  by  radio-
therapy  alone  or  in  combination  with  TKIs
could open new perspectives in the treatment
of this neoplasm. While radiation therapy in
soft tissue sarcomas is highly reported, its role
in GIST management merits extensive investi-
gation. Future research may well abolish the
old concept of GISTs as not sensitive to radia-
tion therapy. 
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Case Report
Figure  1.  (A)  Supraclavicular  localization
of  GIST  before  radiotherapy.  (B)
Supraclavicular localization of GIST after
radiotherapy
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